Hemophilia A and B are X-linked bleeding disorders characterized by partial or complete absence of clotting factors VIII and IX (FVIII and FIX, respectively). FVIII and FIX are critical coagulation ...
DEERFIELD, Ill., March 13, 2015 - Baxter International Inc. (NYSE:BAX) today announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an ...
Morbidity and mortality remain high for patients with acquired hemophilia A, and advances in immunotherapy and hemostatic therapy are needed to improve outcomes. AHA is a rare disorder caused by ...
Factor VIII inhibitor was found in 16 of 77 patients (21 per cent) with severe hemophilia A. In 12 cases with marked inhibition, this became manifest after as few as 20, but no more than 90, ...
HALIFAX, NS, July 20, 2020 /CNW/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of its new CRYOcheck ...
BERLIN, GERMANY — Once-weekly subcutaneous administration of emicizumab (Roche) as prophylaxis reduced or prevented bleeds in people with hemophilia A and inhibitors to factor VIII. More than half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback